

# SENSING AHEAD, CARING MORE

INVESTOR RELATIONS 2025



CGM

**i·sens**

Copyright © i-SENS, Inc. All Right Reserved.

# 00 PROLOGUE

- 01 | Corporate Identity
- 02 | Diabetic CGM Growth (1)(2)
- 03 | Non-diabetic CGM Growth (1)(2)
- 04 | Global CGM Competitiveness
- 05 | CareSens Air: Product Video



CareSens<sup>®</sup> Air

Real-time continuous glucose monitoring  
Seamless management for a healthier life

## Key Products

**BGM** | Blood Glucose Monitoring

A device for a quick blood glucose checks using fingertip samples

**CGM** | Continuous Glucose Monitoring

A skin-attached sensor for real-time tracking of glucose levels

## Customer Segments



Type 1 Diabetes

Type 2 Diabetes

Prediabetes

People without  
Diabetes**World-class R&D capabilities**

- Korea's first CGM developer
- Designed for world-class accuracy & usability
- 46% of R&D staff have master's or PhDs

**Global network & manufacturing scale**

- Expanding global networks via OEM/ODM/PL
- Global reach 114+ countries
- 2.5B BGM strips & 2M CGMs produced annually

**Growth through global expansion**

- Integrated BGM-CGM app boosts user retention
- Partner-led global distribution growth
- CGM for trials builds medical ecosystem

# 02

## Diabetic CGM Growth (1) Rising Patient Population

The global diabetic population is growing, primarily driven by Type 2 Diabetes

### Type 1 Diabetes (Congenital type)

Primarily develops in children and adolescence



Pancreas

Insulin

Blood vessel

- Insulin is not secreted by the pancreas
- An **autoimmune disease** that prevents glucose from being absorbed into cells

### Type 2 Diabetes (Acquired type)

Primarily occurs in middle and old age  
→ Now increasingly seen in younger generations



#### Obesity-related

Caused by adipocyte-induced insulin resistance



#### Other causes beyond obesity


Aging, genetics, lifestyle, mental health, etc.

- Insulin resistance due to acquired factors
- **A metabolic disease** characterized by reduced insulin

Type 1 diabetes is primarily caused by genetic factors, While Type 2 diabetes is primarily caused by changes in lifestyle

#### Global Diabetic Population Forecast

(Unit: 100Mn people)



#### Global Diabetes Prevalence




The Global diabetic population continues to grow, driven primarily by Type 2 Diabetes

# 02

## Diabetic CGM Growth (2) Expanding Reimbursement

Expanded diabetes insurance coverage is driving CGM market growth

### Growing Diabetes Market Size Driven by Diabetes Insurance Coverage



### CGM Usage Among US Diabetes Patients

Despite broad insurance coverage in the U.S., CGM adoption remains low.

#### Type 1 Diabetes Patients



Less than 60%

#### Type 2 Diabetes Patients

Insulin ≥ 3 Times/Day



Less than 50~55%

Based Insulin Users



Less than 20~25%

High Hypoglycemia Risk



Less than 5%

Broader coverage is expected to drive CGM uptake and market growth

Source: Mordor Intelligence (via Gil Korea), 2024, Dexcom, Abbott

### Global CGM Insurance Coverage for Type 2 Diabetes

#### Countries with Insurance Coverage

Country	Coverage Eligibility
<b>U.S.</b>	<ul style="list-style-type: none"> <li>All Insulin Users</li> <li>Non-insulin users with a history of hypoglycemia</li> </ul>
<b>France</b>	<ul style="list-style-type: none"> <li>Insulin users(1-2x/day) with poor glucose control, Basal insulin users</li> </ul>
<b>U.K.</b>	<ul style="list-style-type: none"> <li>Insulin users(≥2 times/day) with a history of hypoglycemia</li> </ul>
<b>Germany</b>	<ul style="list-style-type: none"> <li>Users on basal insulin + oral glucose-lowering drugs</li> </ul>
<b>Canada</b>	<ul style="list-style-type: none"> <li>Multiple daily insulin users in Quebec*</li> </ul>


#### Countries Undergoing Insurance Coverage Discussions

Country	Coverage Eligibility
<b>Korea</b>	<ul style="list-style-type: none"> <li>Reviewing 70% reimbursement for CGM</li> </ul>
<b>Canada</b>	<ul style="list-style-type: none"> <li>Discussion on nationwide CGM coverage expansion</li> </ul>
<b>Australia</b>	<ul style="list-style-type: none"> <li>Policy discussions to expand CGM subsidies</li> </ul>
<b>Brazil</b>	<ul style="list-style-type: none"> <li>CGM under review by national committee for public coverage</li> </ul>

CGM is widely covered for Type 1 Diabetes, with coverage expanding to Type 2


### Global CGM Market Outlook

(Unit: USD Bn)



\* First public reimbursement coverage for adult type 2 diabetes (November 2025)  
Source: Medicare, NICE, National Health Insurance Service, Australian Parliament House (2024), Health Canada, Market Research Future, CONITEC, KKH

Rising demand for insulin resistance management → CGM needed even for normoglycemic individuals



Driven by modern lifestyles, insulin resistance contributes to diabetes and other related conditions




## Metabolic Healthcare: A New Approach to Insulin Resistance

Proactively improving metabolic health to lower insulin resistance

### Prediabetes


Elevated blood glucose due to insulin resistance, but not high enough for a diabetes diagnosis.

Prevalence in Korea (2022)



Global Prevalence Outlook

(Unit: 100Mn people)



### Blood glucose is a key indicator of insulin resistance

Principle of Insulin Resistance



When insulin fails to transport glucose into cells, resistance develops and blood glucose rises




Blood glucose increase  
Blood glucose is the clearest marker of insulin resistance

Rising demand for CGM to monitor blood glucose levels

### Metabolic Syndrome

A cluster of metabolic disorders (e.g., hypertension, obesity), often driven by insulin resistance.

Prevalence in Korea (2021)



Global Prevalence (2024)



Worldwide Adults: ~1 in 3


### How CGM Works



Sensor attachment



Real-time glucose data sent to smartphone app



24/7 monitoring and alerts

Enables 24/7 real-time glucose monitoring

Improve insulin resistance through tailored insights and glucose stability

Source: Korean Society of Cardiovascular and Metabolic Diseases, Korean Diabetes Association, International Diabetes Federation (IDF), Huamani et al., Scientific Reports

CGM use is expanding from diabetes care to general health and wellness



News Growing CGM Adoption among Non-diabetics for Wellness Tracking

**Lifestyle change is key—medication alone isn't enough.**

Continuous Glucose Monitoring (CGM) is gaining attention not only in diabetes care but also for proactive health management. By identifying glucose spikes from specific foods, users can adjust their diets and improve long-term metabolic health.

→ [CGM for Diabetes Prevention](#)


**Why are non-diabetic users, especially young women, adopting CGM?**

Many find value in using CGM to understand how food, exercise, and sleep affect their bodies. Popular content shows how CGM helps optimize workouts, improve eating habits, and track fitness goals.

→ [CGM for Lifestyle & Wellness Optimization](#)

Source: Press Release

## Global Digital Healthcare Market Outlook



Digital health expansion is accelerating access to metabolic care

Source: Grand View Research


## Rise of a CGM-driven Digital Healthcare Ecosystem



CGM is expanding from diabetes care to consumer wellness

Source: Internal data

### User Convenience vs. CGM Accuracy



	i·sens		DEXCOM	Abbott	Medtronic
	CareSens Air	CareSens Air 2 (Upcoming)	G7	Libre 3+	Simplera
Sensor Size	W35.2 xH19.2 xT5.0 mm	W23.6 xH15.8 xT2.9 mm	W27.3 x H24.0 x T4.6 mm	D21.0xT2.9 mm	W28.7x H28.7 x T4.8 mm
Useful Life	15 Days	18 Days	10 Days	15 Days	7 Days
Calibration	Supports Calibration If Needed	Supports Calibration If Needed	Optional Calibration	Not Available	Optional Calibration
Warm-up Time	30 Minutes	20 Minutes	30 Minutes	1 Hour	2 Hour
Data Transfer Interval	Every 5 Minutes	Every 5 Minutes	Every 5 Minutes	Every 1 Minutes	Every 5 Minutes
MARD*	8.7%	Clinical trial completed & preparing for MFDS/CE approvals	8.2%	8.2%	10.2%
Global M/S			35-40% (Est.)	40-45% (Est.)	10-15% (Est.)

W = Width, H = Height, T = Thickness, D = Diameter

\*MARD (Mean Absolute Relative Difference): The average percentage difference between blood glucose values measured by CGM and fingerstick testing. Lower values indicate higher accuracy.

Based on internal data and specifications of commercially available CGM devices as of June 2025

[▶ Watch Video](#)



# 01 i-SENS, The First CGM Company in Korea

- 01 | Growth History
- 02 | ManPower
- 03 | Product Lineup
- 04 | Business Structure and Key Customers
- 05 | Production Infrastructure
- 06 | POCT Product Overview
- 07 | Business Performance
  - 1) 2025 Financial Summary
  - 2) Quarterly Earnings
  - 3) Global Revenue by Region
  - 4) 2026 Financial Preview



CareSens<sup>®</sup> Air

Real-time continuous blood glucose monitoring system  
CareSens Air

# 01

## Growth History

i-SENS is emerging as a global CGM leader with proprietary technology and scalable production



### Core Glucose Monitoring Technology and Business Foundation

- 2000 **Founded i-SENS, Inc.**  
Established Corporate R&D Center
- 2002 Designated as SME and technology development business
- 2003 **Launched CareSens (0.5 µL, 5 sec)**
- 2004 **Acquired CE and ISO 13485 certification**  
Completed construction of the Giheung plant  
Received Minister of Health and Welfare Award
- 2005 **Launched CareSens II**  
Designated as INNO-BIZ
- 2006 **Launched CareSens POP**
- 2007 **Launched CareSens N**  
Completed construction of the Wonju plant
- 2008 **Opened i-SENS China Office**

### And Post-FDA Infrastructure Scaling Global Expansion


- 2009 CareSens received Consumer's Choice Award
- 2011 **Launched CareSens N Mini**
- 2012 Completed construction of the Songdo plant  
**Signed exclusive BGMS supply agreement with the New Zealand government**  
Received \$30M Export Tower Award (49th Trade Day)
- 2013 CareSens received First Brand Award (BGMS category)  
Listed on KOSDAQ  
Selected as a World Class 300 Company  
Received Brand of the Year Award (BGMS category)
- 2015 Launched CareSens NNFC  
**Launched CareSens Dual and CareSens N Premier**  
**Launched CareSens Pro**
- 2016 **Launched CareSens Expert Plus for hospitals**
- 2019 **Launched CareSens N IoT (Partnership with SK Telecom)**  
Received \$100Mn Export Tower Award (56th Trade Day)

### Through Proprietary CGM Technology Becoming a Global CGM Leader

- 2022 Conducted CGM clinical trials (domestic & international)  
Received Industrial Service Merit Medal
- 2023 **Launched CareSens Air**  
Completed construction of the Songdo plant 2
- 2024 **Started development of CareSens Air 2**  
**CareSens Air obtained CE MDR certification**  
Received First Brand Award (13th year)  
Received Minister's Award at Asia LOHAS Fair  
Received Brand of the Year (12th year)  
Received commendation at Healthcare Industry Exchange
- 2025 **Launched upgraded CareSens Air (Korea/EU)**  
**Launched 'My Health Phone' with Samsung**  
**CareSens® Air 2 rated 'Excellent' in Korea Government-wide Medical Device R&D Program Final Evaluation**

### Annual Revenue Trend







(Unit: KRW 100Mn)



Note: K-IFRS standard, 2000-2009 years are K-GAAP standard  
Source: Internal data

i-SENS is led by global experts and powered by strong in-house R&D



## Key Pioneers in Electrochemical CGM Innovation

<b>Founding Pioneer of CGM</b>	<b>Pioneer in CGM Commercialization</b>	<b>Pioneer of CGM Stability</b>
 <p><b>Adam Heller</b> UT Austin Professor Emeritus Recipient of the U.S. National Medal of Technology And Innovation</p> <p style="background-color: #ADD8E6; padding: 2px;">Enzyme-Electrode Connection Technology</p>  <p>Key CGM operating principle → Laid foundation for CGM development</p>	 <p><b>Joseph Wang</b> Founded the Wearable Sensor Center at UCSD Among the world's Most cited scientists</p> <p style="background-color: #90EE90; padding: 2px;">Wearable Sensor Technology</p>  <p>Miniaturized sensors Enabled patch-type CGM</p>	 <p><b>Mark Meyerhoff</b> University of Michigan Professor Emeritus 2xACS Award* Recipient</p> <p style="background-color: #9370DB; padding: 2px;">NO** Emission Sensor Technology</p>  <p>Regulating the Body's Bioreactions → Significant Increase in CGM usability</p>

All three core CGM technologies shaped the industry and directly influenced key companies.

 <p><b>Abbott</b></p>  <p>TheraSense, founded By Prof. Adam Heller Later acquired by Abbott</p>	 <p><b>Dexcom</b></p>  <p>Researches from Prof. Wang's lab contributed to Dexcom's CGM development</p>	 <p><b>i-sens</b></p>  <p>Key researchers Trained under Prof. Mark Meyerhoff</p>
---	--	--

## Workforce Composition and R&D Investment



\*An award presented by the American Chemical Society (ACS) to researchers who have made globally influential achievements, signifying the highest level of authority in the chemical field.

\*\*Nitric Oxide, a gaseous molecule in the body, plays a crucial role in vasodilation, immune regulation, and thrombosis inhibition. Applying this to CGM prevents the sensor from being recognized as a foreign substance by the body, thereby increasing the CGM's lifespan.  
Source: Internal data


# 03

## Product Lineup

BGM and CGM complement each other in managing blood glucose, with unique strengths and use cases

### Daily Glucose Monitoring Routine

Stable glucose management requires both BGM and CGM → Patients may test with BGM up to 8 times daily





Product	BGM					CGM				
Category	Strip		Meter			<p>First CGM Developed and Launched in Korea</p>				
Pros and Cons	<p><b>Advantage</b></p> <ul style="list-style-type: none"> <li>Low Price</li> <li>High Accuracy</li> </ul> <p><b>Disadvantage</b></p> <ul style="list-style-type: none"> <li>Fingerstick Pain</li> <li>Frequent Measurement</li> <li>No Trend Visibility</li> </ul>					<p><b>Advantage</b></p> <ul style="list-style-type: none"> <li>No Fingerstick Pain</li> <li>High/Low Glucose Alerts</li> <li>Trend Visibility</li> </ul> <p><b>Disadvantage</b></p> <ul style="list-style-type: none"> <li>High Price</li> <li>Lower Accuracy than BGM</li> </ul>				
Target Users	Type 1 and 2 diabetes patients					Type 1 and 2 diabetes, prediabetes, general public				
Measurement Method	Measures glucose by obtaining a blood sample					Measures glucose continuously via a sensor				
Measurement Site	Fingertip					Back of upper arm				
Measurement Sample	Capillary blood					Interstitial fluid (blood X)				
Replacement Cycle	Single use					15 days from sensor attachment				

Source: Internal data

# Business Structure and Key Customers

Own brand & OEM/ODM channels → Expand BGM OEM/ODM references to CGM

Leading BGM Market Share in Korea (over 50%)



Note: Based on Q4 2025 revenue  
Source: Internal data

# 05

## Production Infrastructure


Annual production capacity of 2.5 billion BGM strips and 2 million CGM sensors

### BGM & CGM Production Capacity




#### Songdo 1 and 2 Plants

**Songdo 1 Plant**



**Songdo 2 Plant**



- Location: **Songdo, Incheon**
- Products Manufactured: **BGM strips, CGM Sensors**
- Annual Production Capacity
  - BGM strips: **800 million units**
  - CGM Sensors: **0.5 million units + 1.5 million units (Songdo 2 Plant)**

**Building 3.4 million CareSens Air 2 sensor capacity & semi-automated POC cartridge line (2026-Q1 2027)**

**Add CGM line at Songdo Plant 2, bringing total annual capacity to 5.4M units**

#### Wonju Plant



- Location: **Munmak-eup, Wonju-si, Gangwon-do**
- Products: **BGM strips**
- Annual Production Capacity: **1.4 billion units**



**Securing global supply stability as the largest domestic strip production base**

#### China Plant



- Location: **Zhangjiagang City, Jiangsu Province**
- Products: **BGM strips**
- Annual Production Capacity: **300 million units**

**Supporting global demand and China market entry**



Note: Average Daily Production Quantity × Working Days × Operating Months = Annual Total Production Capacity. The above production capacity is based on a 1 shift (8h of work/day)  
Source: Internal data

Installed analyzers driving recurring cartridge sales → Key growth driver for POCT

## POCT Product Lineup

A diverse POCT product lineup and the potential for continuous revenue from diagnostic equipment requiring consumables.

### High-Value Professional Diagnostic Products

#### Hospital Diabetes Management POCT Products



##### Clinical Chemistry Analyzer

- Analytes: HbA1c, \*ACR, GA, CRP
- All-in-one cartridge for fast and accurate results
- Rapid turnaround time (HbA1c: 4min 20sec, ACR: 7min)

Global Market Size : USD 0.98Bn



##### BGM for Hospitals

- Hospital-use device for blood glucose & ketone measurement
- Supports Wi-Fi and USB for real-time data transfer and automatic software updates, enabling seamless hospital data integration

#### PT/INR Coagulation Testing Solutions



##### PT/INR Blood Coagulation Meter

- Product of U.S. subsidiary, 'CoaguSense
- Prothrombin Time tests: Testing for bleeding disorders, including hemophilia and coagulation abnormalities, primarily used for patients on warfarin

Global Market Size : USD 1.69Bn



##### Blood Electrolyte Analyzer

- Launched in 2009
- **No.1 in Korea by installed base**
- Measures: Hct, Na, K, Cl (existing) + Ca, Mg (in development)

Global Market Size: USD 2.84Bn



##### Blood Gas Analyzer

- Upgraded model launched in 2020
- Measures: pH, pCO<sub>2</sub>, pO<sub>2</sub>, Hct, Na, K, Cl, iCa, Glucose, Lactate



##### Immunoassay Analyzer

- Detects key cardiovascular biomarkers
- **Expandable platform for future marker integration**


Global Market Size: USD 1.81Bn

## Sustained Cartridge-Driven Growth

### POCT Revenue Trend

Achieved KRW 46.8 billion in 2025 with a 15.6% CAGR('16~'25)


(Unit: KRW 100Mn)



### Cartridge Product Sales and Share Trends

Cartridges Account for 45% of POCT Sales

(Unit: KRW 100Mn)



\*ACR (Albumin/Creatinine Ratio): The ratio of albumin to creatinine levels, enabling a more accurate diagnosis of kidney function  
 Note1: USD 1 = KRW 1,400, Note2: Global Market Size (2024)  
 Based on Markets and Markets, K-HID, QYR, Data Bridge, Horizon Grand View Research, Kalorama, Biomerieux and Internal data

## Consolidated Income Statement

(Unit: KRW Mn)

구분	2023	2024	2025	YoY
Revenue	265,120	291,138	315,445	8%
Cost of Sales	159,061	177,604	190,184	7%
	60%	61%	60%	
Gross Profit	106,059	113,534	125,261	11%
	40%	39%	40%	
SG&A	95,130	110,876	117,375	6%
	36%	38%	37%	
Operating Profit	10,929	2,658	7,887	212%
	4%	1%	3%	
Non-operating income	-4,797	-1,005	-18,556	
Income tax expense	2,728	3,605	-3,979	
Net Income	3,404	-1,953	-6,691	-243%
	1%	-1%	-2%	

Note: K-IFRS Consolidated Basis

## Key Highlights

## Revenue

- **CGM Revenue: KRW 17.6Bn**  
(Domestic KRW 10.9Bn, Overseas KRW 6.7Bn)

- **Annual Capacity of 2Mn units Secured**  
(Completion of automated production line at Songdo 2 Plant)

## P&amp;L


- **Gross Profit Increase**  
Increase in gross profit driven by higher CGM sales and improved profitability of overseas subsidiaries  
Margin expansion limited due to increased other expenses related to facility investment and production capacity expansion

- **Operating Profit Increase**  
Operating profit increased by KRW 5.2Bn  
R&D and patent/legal-rated expenses increased (KRW 5.4Bn)


- **Non-operating Items**  
Decrease in disposal and valuation gains (-KRW 16Bn YoY)  
Increase in equity method losses (KRW 0.8Bn)  
Recognition of income tax benefit due to increased tax refunds and carryforward tax credits



Quarterly Revenue



Quarterly Operating Profit



Q4 2025 Earnings Results

- Revenue grew by 2.9% YoY
- Operating profit of KRW 2.1Bn (Turned to profit)
- Net loss of KRW 8.9Bn (Continued loss)

Q4 2025 Earnings Review


- CGM revenue growth and expansion of overseas sales drove revenue increase of approximately KRW 2.3Bn YoY
- Operating profit turned to profit on higher sales and improved overseas subsidiary profitability despite higher R&D and clinical costs
- Net loss was driven by non-cash valuation losses and goodwill impairment among non-operating items

Note: K-IFRS Consolidated basis

Revenue Breakdown by Region - 2025

i-SENS Overseas Subsidiaries 2024 2025

(Unit: KRW 100Mn)



Note: K-IFRS Consolidated basis

CGM overseas sales growth and revenue expansion across all business segments, along with cost reduction initiatives  
Laying the foundation for full-scale CGM business growth through clinical expansion and increased capacity

### Key Highlights

<b>Revenue</b>	<ul style="list-style-type: none"> <li>• <b>Headquarters Revenue Growth</b> Revenue growth across all business segments including CGM Ongoing participation in BGM/CGM overseas tenders and reimbursement listings in key markets</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Subsidiary Revenue Growth</b> Revenue growth expected across most subsidiaries YoY</li> </ul>
<b>CGM</b>	<ul style="list-style-type: none"> <li>• <b>2026 CGM Revenue Target: KRW 40.0Bn</b> (Domestic 16.0Bn / Overseas KRW 24.0Bn)</li> <li>• <b>2025 CGM Revenue: KRW 17.6Bn</b> (Domestic KRW 10.9Bn / Overseas KRW 6.7Bn, Exceeded the initial target by 17.3%)</li> <li>• <b>2026 Key Events:</b> Q1 : Completed CGM supply agreement with LifeScan, initiated CareSens Air 2 U.S. pilot trial, completed CGM pilot trial in China Q2 : MFDS and CE submissions for pediatric use expansion of CareSens Air, initiate CGM pivotal trial in China 3Q : MFDS and CE approvals for pediatric use expansion of CareSens Air, complete CareSens Air 2 U.S. pilot trial, CGM submission to NMPA, China 4Q : Initiation of CareSens Air 2 U.S. pivotal trial</li> </ul>	
<b>Manufacturing</b>	<ul style="list-style-type: none"> <li>• <b>CGM Production Capacity: 2Mn → 5.4M units in Q1 2027</b> (3.4M units CareSens Air 2 sensors) Strengthening global supply stability in response to rising demand</li> </ul>	
<b>Cost Management</b>	<ul style="list-style-type: none"> <li>• <b>Margin Improvement through Cost Reduction</b> BGM COGS savings via overseas production (Vietnam, China): 45% of total production in 2026, to expand further</li> </ul>	

# 02 Advancing as a Global Top-Tier CGM Company

01 | CGM Future Plans

02 | CGM Global Launch Plan

03 | Global Market Expansion Strategy

- 1) Partnerships with Global Players
- 2) Support for Global Clinical Trials
- 3) Localized Manufacturing Capabilities
- 4) Open Connected Ecosystem

04 | Vision & Value-up Plan




Real-time continuous blood glucose monitoring system  
CareSens Air

# 01

## CGM Future Plans CareSens Air Development and Launch Timeline

CareSens Air aims for age 2+ approval in 2026 following domestic and CE approvals  
 CareSens Air 2 launches in Korea in 2027, followed by Europe in 2027 and the U.S. in 2028

### CareSens Air Development and Launch Timeline



\*OTC(Over the Counter): Medicines available without a prescription, sold at pharmacies or other retail channels  
 \*\*Based on current plans; timelines are subject to final confirmation as the clinical target has been changed from CareSens Air 1 to CareSens Air 2  
 Note: Upgrade includes: Reduced warm-up time (2h → 30 min), supports calibration if needed, non-adjunctive use approved

Expansion of global footprint through product launches in multiple countries


## CareSens Air

- 2025: Launched in 27 countries
- 2026: Launch in 9 additional countries



## CareSens Air 2

- 2027: Launch in South Korea and Europe
- 2028: Launch in U.S.



Source: Internal data

Expanding global presence through multi-faceted strategies


1

## Enhancing Access and Global Reach Through Strategic Partnerships



2

## Accelerating Ecosystem Growth via CGM Supply for Clinical Trials




3

## Building Local Manufacturing Capabilities Through Technology Transfer



4

## Fostering Long-term Growth Through an Open Connected Ecosystem




Customer acquisition, distribution expansion, clinical adoption, and manufacturing competitiveness  
 → Accelerating Global CGM Revenue Growth

Source: Internal data

Expanding partnerships based on globally competitive CGM products

## 1 Smart Device CGM Integration Partnership


Unified tracking of diet, activity, and glucose data



Driving B2C Expansion via Global Smart Health Partnerships

## 2 R&D Partnership for Artificial Pancreas Development


Joint development of AID (Automated Insulin Delivery) system



Targeting High-Risk Patients with Integrated CGM-Pump Solutions

## 3 Distribution Partnership via CGM-Linked Product Sales

AI-based glucose coaching connected to i-SENS product sales



Expanding Global Reach through Data-Linked Sales Channels

## 4 OEM & ODM Distribution Partnership

Establishing distribution infrastructure through partnerships



Rapid market entry and revenue expansion via OEM/ODM model

Strengthening product competitiveness → Expanding partnerships → Accelerating global revenue growth

Source: Internal data

Expanding clinical adoption through accumulated clinical data → CGM revenue growth

**i.sens** CGM Provided  
For glucose monitoring



### Hospitals, Research Centers, and CROs

Clinical Trial A

Clinical Trial B

Clinical Trial C

...

Trials conducted with CGM in use  
Real-time validation of drug/device efficacy  
Contributing to CGM as global standard



**Medical Ecosystem**  
Expanding presence  
In the global  
Medical ecosystem

### Revenue Generation

(Creation of new revenue streams)



Trial supply  
To hospitals  
And research sites

Drives new customer  
Acquisition  
And contract sales

### Brand Building via Clinical Trials (incl. PMCF\*)

→ Generating promotional and marketing impact



Product use  
in clinical trials

Build objective trust  
via clinical experience

Reinforce field  
Credibility  
via repeated use

'Strengthen  
CareSens Air  
brand trust

Expand promotional effect through user experience

### User Data Collection

→ Algorithm Optimization



Collecting  
diverse user data

Ongoing  
algorithm  
refinement

Expansion of hospital and institutional contracts based on clinical supply → New revenue generation

\*PMCF: Post-Market Clinical Follow-up, Periodic clinical follow-up observation after medical device market release  
Source: Internal data

Benefits of Establishing a Local Production System

Price competitiveness through tariff reduction and local production


Market entry facilitation via public procurement and regulatory alignment

Supply stability via local manufacturing, enabling large-scale contracts

Distribution network expansion through local partnerships

Local manufacturing partner-based lock-in structure → enabling long-term supply agreements and recurring revenue

BGM Local Production System




CGM Expansion

Local manufacturing-based CGM global expansion → Emerging market revenue growth

Source: Internal data

Starting with EMR integration, connecting to digital healthcare across medical, insurance, and wellness to create real value



Creating true value through connectivity to digital healthcare expanding into medical, insurance, and wellness

i·sens

## Achieve CGM sales growth and market revaluation with a **mid- to long-term PSR vision of 4**

('25 PSR 1.4x)

### Pipeline

#### Product Development and Launch

- CareSens Air: Expanded age indication in 2026
- CareSens Air 2
  - ✓ Approval and launch in Korea and Europe in 2027
  - ✓ Approval and market entry in the U.S. in 2028

### Sales Growth

#### 2030 CGM Sales

## KRW 1 Trillion

Mid- to long-term strategic direction considering global approval timelines and production capacity expansion

### Shareholder Return

#### Shareholder Return Rate

## 30%

#### 2030 Cumulative Treasury Stock Cancellation

## KRW 30 Billion

Aim for the mid- to long-term within a scope that preserves growth investment and financial stability

In the CGM growth phase, a sales-based valuation (PSR) is appropriate, with re-rating potential

# 03 APPENDIX

01 | Company Overview

02 | Consolidated Financial Statements



CareSens<sup>®</sup> Air 2




## Global Corporate Structure



Source: Internal data

## Company Overview

Company Name	i-SENS [KOSDAQ 099190]
Representative Directors	Geun Sig Cha(CEO), Hakhyun Nam(CEO)
Principal Business	Electrochemical Diagnostic Biosensor
Date of Establishment	May 2000
Listing Date	January 2013
Capital Stock	KRW 13.8B
Number of Employees	960
Address	43, Banpo-daero 28-gil, Seocho-gu, Seoul
Website	www.i-sens.com





## Balance Sheet

(Unit: KRW Mn)

Category	2021	2022	2023	2024	2025
Current Assets	207,653	217,187	207,526	270,907	253,710
Non-current Assets Held for Sale	-	-	10,245	4,672	4,672
Non-current Assets	221,526	232,383	281,045	315,289	319,281
<b>Total Assets</b>	<b>429,179</b>	<b>449,570</b>	<b>498,816</b>	<b>590,868</b>	<b>577,663</b>
Current Liabilities	38,391	74,563	139,305	112,085	166,913
Non-current Liabilities	106,048	70,251	56,016	135,802	72,429
<b>Total Liabilities</b>	<b>144,439</b>	<b>144,814</b>	<b>195,321</b>	<b>247,887</b>	<b>239,342</b>
Capital Stock	6,869	6,877	13,759	13,821	13,868
Capital Surplus	46,205	47,013	41,697	42,971	44,395
Other Equity Items	(6,569)	(4,653)	(5,092)	2,701	2,379
Other Comprehensive Income	23,303	22,631	21,861	56,760	55,580
Assets Held for Sale Related Other Comprehensive Income	-	-	548	250	250
Retained Earnings	198,525	213,942	211,577	208,192	198,775
Non-controlling Interests	16,408	18,946	19,145	18,286	23,074
<b>Total Equity</b>	<b>284,740</b>	<b>304,756</b>	<b>303,495</b>	<b>342,981</b>	<b>338,321</b>

Note: K-IFRS Consolidated Financial Statements Standard

## Income Statement

(Unit: KRW Mn)

Category	2021	2022	2023	2024	2025
Revenue	232,935	264,837	265,120	291,138	315,445
Cost of Revenue	130,870	159,351	159,061	177,604	190,184
<b>Gross Profit</b>	<b>102,065</b>	<b>105,486</b>	<b>106,059</b>	<b>113,534</b>	<b>125,261</b>
Selling and Administrative Expenses	67,238	85,679	95,130	110,876	117,375
<b>Operating profit</b>	<b>34,827</b>	<b>19,807</b>	<b>10,929</b>	<b>2,658</b>	<b>7,887</b>
Non-Operating Profit/Loss	(2,653)	1,696	(2,818)	739	(16,049)
Equity Method Gains and Losses	(1,433)	(2,350)	(1,978)	(1,745)	(2,507)
<b>Profit before Income Tax</b>	<b>30,741</b>	<b>19,153</b>	<b>6,132</b>	<b>1,652</b>	<b>(10,669)</b>
Income Tax Expense	5,590	3,245	2,728	3,605	(3,979)
<b>Net Income</b>	<b>25,151</b>	<b>15,908</b>	<b>3,404</b>	<b>(1,953)</b>	<b>(6,691)</b>